New combination therapy may improve outcomes for women with triple-negative breast cancer.

I-spy 2 trial, innovative multidrug resistance, phase II trial cancer led to a positive result in the first drugs to complete testing in breast cancer trial. Using the standard chemotherapy for women with triple-negative breast cancer improved outcomes I spy carboplatin combination chemotherapy and molecular targeted drugs veliparib 2 from trial (UCSF Helen Diller family comprehensive cancer led by researchers from the Center) in and results will be announced in 2013, according to the San Antonio Breast Cancer Symposium held 12/10-14.

View the original article here